Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ-234 in Healthy Volunteers and Moderate to Severe Atopic Dermatitis
NCT07453602Phase 1Recruiting
- Sponsor
- Arcutis Biotherapeutics
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing ARQ-234 with Placebo (2 arms). Primary endpoints: Adverse Events and Serious Adverse Events at 30 weeks and Eczema Area and Severity Index at 16 weeks. Started Mar 2026; status: recruiting.
02
Drugs
ARQ-234
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07453602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453602.